Published in Pain on December 06, 2006
Oxycodone and Pregabalin for the Treatment of Oncological Neuropathic Pain | NCT00637975
Pharmacogenetic Morphine Spine Study | NCT01839461
Patient Controlled Analgesia Pharmacogenetic Study | NCT01731873
Multicenter Perioperative Opioid Pharmacogenetic Study | NCT01495611
Comprehensive Study of Post-surgical Pain After Pectus or Spine Surgery | NCT04031716
Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA (2013) 2.34
Pain and stress in a systems perspective: reciprocal neural, endocrine, and immune interactions. J Pain (2007) 1.80
Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. Proc Natl Acad Sci U S A (2009) 1.76
Variation in the mu-opioid receptor gene (OPRM1) is associated with dispositional and neural sensitivity to social rejection. Proc Natl Acad Sci U S A (2009) 1.74
OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend (2010) 1.55
Progress in genetic studies of pain and analgesia. Annu Rev Pharmacol Toxicol (2009) 1.43
Molecular epidemiology, cancer-related symptoms, and cytokines pathway. Lancet Oncol (2008) 1.19
Increased sensitivity to thermal pain following a single opiate dose is influenced by the COMT val(158)met polymorphism. PLoS One (2009) 1.12
Genetic contributions to clinical pain and analgesia: avoiding pitfalls in genetic research. J Pain (2009) 1.07
An imaging genetics approach to understanding social influence. Front Hum Neurosci (2012) 1.04
Zebrafish: a model for the study of addiction genetics. Hum Genet (2011) 1.03
Genome-wide association study of acute post-surgical pain in humans. Pharmacogenomics (2009) 1.03
μ-Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. Anesthesiology (2012) 1.03
The influence of tumor necrosis factor-alpha -308 G/A and IL-6 -174 G/C on pain and analgesia response in lung cancer patients receiving supportive care. Cancer Epidemiol Biomarkers Prev (2008) 0.96
Recent advances in the use of opioids for cancer pain. J Pain Res (2009) 0.95
Ethnicity interacts with the OPRM1 gene in experimental pain sensitivity. Pain (2012) 0.94
Pain following the repair of an abdominal hernia. Surg Today (2009) 0.93
Precise genetic mapping and integrative bioinformatics in Diversity Outbred mice reveals Hydin as a novel pain gene. Mamm Genome (2014) 0.91
Genetic variability at COMT but not at OPRM1 and UGT2B7 loci modulates morphine analgesic response in acute postoperative pain. Eur J Clin Pharmacol (2013) 0.89
The genetic influence on the cortical processing of experimental pain and the moderating effect of pain status. PLoS One (2010) 0.89
Genetics of pain perception, COMT and postoperative pain management in children. Pharmacogenomics (2014) 0.86
Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside? J Pain Res (2013) 0.86
The associations between OPRM 1 and COMT genotypes and postoperative pain, opioid use, and opioid-induced sedation. Biol Res Nurs (2012) 0.86
Symptom clusters of pain, depressed mood, and fatigue in lung cancer: assessing the role of cytokine genes. Support Care Cancer (2013) 0.85
Drug response profiles to experimental pain are opioid and pain modality specific. J Pain (2010) 0.84
Genotyping test with clinical factors: better management of acute postoperative pain? Int J Mol Sci (2015) 0.84
The mu opioid receptor A118G gene polymorphism moderates effects of trait anger-out on acute pain sensitivity. Pain (2008) 0.83
Polymorphism of A118G in μ-opioid receptor gene is associated with risk of esophageal squamous cell carcinoma in a Chinese population. Int J Clin Oncol (2012) 0.83
Pharmacogenetics of analgesic drugs. Br J Pain (2013) 0.83
The val158met polymorphism of human catechol-O-methyltransferase (COMT) affects anterior cingulate cortex activation in response to painful laser stimulation. Mol Pain (2010) 0.83
Candidate gene polymorphisms predicting individual sensitivity to opioids. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.82
Pharmacogenetics of OPRM1. Pharmacol Biochem Behav (2013) 0.81
Pharmacogenetics of chronic pain and its treatment. Mediators Inflamm (2013) 0.81
Analgesia and central side-effects: two separate dimensions of morphine response. Br J Clin Pharmacol (2013) 0.80
Elucidation of mu-Opioid Gene Structure: How Genetics Can Help Predict Responses to Opioids. Eur J Pain Suppl (2011) 0.80
Life-threatening adverse events following therapeutic opioid administration in adults: is pharmacogenetic analysis useful? Pain Res Manag (2013) 0.80
Combined analysis of circulating β-endorphin with gene polymorphisms in OPRM1, CACNAD2 and ABCB1 reveals correlation with pain, opioid sensitivity and opioid-related side effects. Mol Brain (2013) 0.80
Variations in opioid receptor genes in neonatal abstinence syndrome. Drug Alcohol Depend (2015) 0.80
Individualized pain medicine. Drug Discov Today Ther Strateg (2009) 0.79
Subjective health complaints in patients with lumbar radicular pain and disc herniation are associated with a sex - OPRM1 A118G polymorphism interaction: a prospective 1-year observational study. BMC Musculoskelet Disord (2014) 0.78
Buprenorphine signalling is compromised at the N40D polymorphism of the human μ opioid receptor in vitro. Br J Pharmacol (2014) 0.78
MAPK1/ERK2 as novel target genes for pain in head and neck cancer patients. BMC Genet (2016) 0.76
Human pain and genetics: some basics. Br J Pain (2013) 0.76
Genomic methods for clinical and translational pain research. Methods Mol Biol (2012) 0.76
Pharmacogenomic incidental findings in 308 families: The NIH Undiagnosed Diseases Program experience. Genet Med (2016) 0.75
Pharmacogenomic considerations in opioid analgesia. Pharmgenomics Pers Med (2012) 0.75
Pain management with morphine: variation in analgesic response secondary to genetic polymorphisms. Ther Clin Risk Manag (2012) 0.75
OPRM1 c.118A>G Polymorphism and Duration of Morphine Treatment Associated with Morphine Doses and Quality-of-Life in Palliative Cancer Pain Settings. Int J Mol Sci (2017) 0.75
Association of maternal and infant variants in PNOC and COMT genes with neonatal abstinence syndrome severity. Am J Addict (2016) 0.75
The pharmacogenomics of pain management: prospects for personalized medicine. J Pain Res (2016) 0.75
Genome-wide association study suggests common variants within RP11-634B7.4 gene influencing severe pre-treatment pain in head and neck cancer patients. Sci Rep (2016) 0.75
The correlation between post-operative fentanyl requirements and μ-opioid receptor gene A118G polymorphism in patients undergoing radical gastrectomy. Exp Ther Med (2013) 0.75
Morphine-induced antinociception and reward in "humanized" mice expressing the mu opioid receptor A118G polymorphism. Brain Res Bull (2015) 0.75
Genetic Testing for Opioid Pain Management: A Primer. Pain Ther (2017) 0.75
Prospective replication study implicates the catechol-O-methyltransferase Val(158)Met polymorphism as a biomarker for the response to morphine in patients with cancer. Biomed Rep (2017) 0.75
Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics (1996) 6.83
Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet (2004) 5.87
The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer (1984) 5.24
COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science (2003) 4.72
Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A (1998) 4.67
Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer (1980) 4.31
Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs. Clin Pharmacol Ther (2006) 2.59
The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J Pain (2005) 2.23
Genetic influence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament. Pain (2004) 2.17
Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. Hum Mol Genet (2000) 2.05
The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain (2005) 2.00
The genetic mediation of individual differences in sensitivity to pain and its inhibition. Proc Natl Acad Sci U S A (1999) 1.96
Pain measurement tools and methods in clinical research in palliative care: recommendations of an Expert Working Group of the European Association of Palliative Care. J Pain Symptom Manage (2002) 1.91
Molecular mechanisms of drug addiction. J Neurosci (1992) 1.88
Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. Exp Brain Res (1998) 1.80
Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance? Neurosignals (2005) 1.80
Candidate gene studies of human pain mechanisms: methods for optimizing choice of polymorphisms and sample size. Anesthesiology (2004) 1.78
The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand (2004) 1.77
A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem (2000) 1.65
The Norwegian brief pain inventory questionnaire: translation and validation in cancer pain patients. J Pain Symptom Manage (2002) 1.58
Human catechol O-methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes. Mol Psychiatry (2004) 1.53
Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet (2004) 1.51
Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat (2006) 1.49
The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci U S A (1999) 1.41
The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2005) 1.39
Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Lett (1994) 1.39
A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther (2004) 1.39
Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology (2000) 1.28
Current evidence for a genetic modulation of the response to analgesics. Pain (2006) 1.27
Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand (2005) 1.27
Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum. Neuroscience (1993) 1.26
The pharmacology of mu analgesics: from patients to genes. Neuroscientist (2001) 1.11
Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity? Anesthesiology (2002) 1.09
Single nucleotide polymorphisms in the human mu opioid receptor gene alter basal G protein coupling and calmodulin binding. J Biol Chem (2001) 1.06
Detection of single nucleotide polymorphisms of the human mu opioid receptor gene by hybridization or single nucleotide extension on custom oligonucleotide gelpad microchips: potential in studies of addiction. Am J Med Genet (2000) 1.00
IL-5 and thromboxane A2 receptor gene polymorphisms are associated with decreased pulmonary function in Korean children with atopic asthma. J Allergy Clin Immunol (2005) 0.96
No evidence of association or interaction between the IL4RA, IL4, and IL13 genes in type 1 diabetes. Am J Hum Genet (2005) 0.96
Pain genes?: natural variation and transgenic mutants. Annu Rev Neurosci (2000) 0.95
Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers. Pharmacogenomics J (2006) 0.93
CBLB variants in type 1 diabetes and their genetic interaction with CTLA4. J Leukoc Biol (2005) 0.92
Allelic variation S268P of the human mu-opioid receptor affects both desensitization and G protein coupling. Mol Pharmacol (2000) 0.90
Genetics and variability in opioid response. Eur J Pain (2005) 0.87
Gene-gene interaction between interleukin-6 and interleukin-10 reduces AD risk. Neurology (2004) 0.86
The pharmacogenetics of analgesia: toward a genetically-based approach to pain management. Pharmacogenomics (2001) 0.84
Assessing pain candidate gene studies. Pain (2004) 0.83
Allelic and somatic variations in the endogenous opioid system of humans. Pharmacol Ther (2001) 0.81
Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet (2008) 16.17
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature (2008) 16.10
Definition and classification of cancer cachexia: an international consensus. Lancet Oncol (2011) 7.78
Lung cancer susceptibility locus at 5p15.33. Nat Genet (2008) 5.99
A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet (2009) 5.62
Human and bacterial oxidative demethylases repair alkylation damage in both RNA and DNA. Nature (2003) 5.49
Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol (2013) 5.07
Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain (2006) 4.96
Availability and integration of palliative care at US cancer centers. JAMA (2010) 4.51
Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res (2004) 4.48
Health-related quality of life associated with chronic conditions in eight countries: results from the International Quality of Life Assessment (IQOLA) Project. Qual Life Res (2004) 4.33
A risk model for prediction of lung cancer. J Natl Cancer Inst (2007) 4.25
Ignoring linkage disequilibrium among tightly linked markers induces false-positive evidence of linkage for affected sib pair analysis. Am J Hum Genet (2004) 3.83
Investigation of the fine structure of European populations with applications to disease association studies. Eur J Hum Genet (2008) 3.65
Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage (2011) 3.44
HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A (2004) 3.43
Palliative cancer care a decade later: accomplishments, the need, next steps -- from the American Society of Clinical Oncology. J Clin Oncol (2009) 3.36
Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol (2012) 3.26
Mutations in transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms and dissections. Circulation (2005) 2.77
Prognostic factors in advanced cancer patients: evidence-based clinical recommendations--a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol (2005) 2.76
CUBN is a gene locus for albuminuria. J Am Soc Nephrol (2011) 2.70
Mutations in myosin light chain kinase cause familial aortic dissections. Am J Hum Genet (2010) 2.67
Low copy number DNA template can render polymerase chain reaction error prone in a sequence-dependent manner. J Mol Diagn (2005) 2.66
Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol (2002) 2.65
Supportive versus palliative care: what's in a name?: a survey of medical oncologists and midlevel providers at a comprehensive cancer center. Cancer (2009) 2.58
The association between headache and Val158Met polymorphism in the catechol-O-methyltransferase gene: the HUNT Study. J Headache Pain (2006) 2.27
The validity of EORTC QLQ-C30 fatigue scale in advanced cancer patients and cancer survivors. Palliat Med (2003) 2.18
hUNG2 is the major repair enzyme for removal of uracil from U:A matches, U:G mismatches, and U in single-stranded DNA, with hSMUG1 as a broad specificity backup. J Biol Chem (2002) 2.18
Genetic variants on 15q25.1, smoking, and lung cancer: an assessment of mediation and interaction. Am J Epidemiol (2012) 2.16
Ensuring quality cancer care: a follow-up review of the Institute of Medicine's 10 recommendations for improving the quality of cancer care in America. Cancer (2011) 2.15
Dehydration in cancer patients: to treat or not to treat. J Support Oncol (2004) 2.15
Which domains should be included in a cancer pain classification system? Analyses of longitudinal data. Pain (2012) 2.07
Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer (2002) 2.01
The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain (2005) 2.00
The use of very-low-dose methadone for palliative pain control and the prevention of opioid hyperalgesia. J Palliat Med (2013) 2.00
Association between a 15q25 gene variant, smoking quantity and tobacco-related cancers among 17 000 individuals. Int J Epidemiol (2009) 1.97
Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer. Cancer (2010) 1.97
The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer (2005) 1.97
A cross-sectional study on prevalence of pain and breakthrough pain among an unselected group of outpatients in a tertiary cancer clinic. Support Care Cancer (2014) 1.97
Genome-wide association study of glioma and meta-analysis. Hum Genet (2012) 1.96
Tidsskr Nor Laegeforen (2016) 1.94
Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.93
Estimating the prevalence of chronic pain: validation of recall against longitudinal reporting (the HUNT pain study). Pain (2012) 1.92
The effect of a physical exercise program in palliative care: A phase II study. J Pain Symptom Manage (2006) 1.92
Delirium in advanced cancer patients. Palliat Med (2004) 1.92
Pain measurement tools and methods in clinical research in palliative care: recommendations of an Expert Working Group of the European Association of Palliative Care. J Pain Symptom Manage (2002) 1.91
A genome-wide association study identifies a locus on chromosome 14q21 as a predictor of leukocyte telomere length and as a marker of susceptibility for bladder cancer. Cancer Prev Res (Phila) (2011) 1.86
Ask-Advise-Connect: a new approach to smoking treatment delivery in health care settings. JAMA Intern Med (2013) 1.86
Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial. J Clin Oncol (2004) 1.85
Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis (2009) 1.84
Chromosome 7p11.2 (EGFR) variation influences glioma risk. Hum Mol Genet (2011) 1.83
Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls. Hum Mol Genet (2012) 1.77
Interval between first palliative care consult and death in patients diagnosed with advanced cancer at a comprehensive cancer center. J Palliat Med (2008) 1.76
Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network. Palliat Med (2005) 1.75
Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine (2004) 1.70
Assessment and classification of cancer breakthrough pain: a systematic literature review. Pain (2010) 1.70
Associations between recreational exercise and chronic pain in the general population: evidence from the HUNT 3 study. Pain (2011) 1.70
Interval between palliative care referral and death among patients treated at a comprehensive cancer center. J Palliat Med (2005) 1.67
Patient-physician communication about code status preferences: a randomized controlled trial. Cancer (2013) 1.66
NCCN clinical practice guidelines in oncology: palliative care. J Natl Compr Canc Netw (2009) 1.66
Prevalence and predictors of cognitive dysfunction in opioid-treated patients with cancer: a multinational study. J Clin Oncol (2011) 1.61
uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci U S A (2006) 1.61
Association between a name change from palliative to supportive care and the timing of patient referrals at a comprehensive cancer center. Oncologist (2011) 1.61
Pain assessment tools: is the content appropriate for use in palliative care? J Pain Symptom Manage (2006) 1.61
Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. J Clin Oncol (2013) 1.59
An international multicentre validation study of a pain classification system for cancer patients. Eur J Cancer (2010) 1.59
Which patients with cancer die at home? A study of six European countries using death certificate data. J Clin Oncol (2010) 1.58
The Norwegian brief pain inventory questionnaire: translation and validation in cancer pain patients. J Pain Symptom Manage (2002) 1.58
The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study. J Palliat Med (2010) 1.57
Estimation of odds ratios of genetic variants for the secondary phenotypes associated with primary diseases. Genet Epidemiol (2011) 1.57
Palliative management of fatigue at the close of life: "it feels like my body is just worn out". JAMA (2007) 1.57
p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. J Natl Cancer Inst (2002) 1.56
Bedside clinical signs associated with impending death in patients with advanced cancer: preliminary findings of a prospective, longitudinal cohort study. Cancer (2015) 1.56
Mediating effects of smoking and chronic obstructive pulmonary disease on the relation between the CHRNA5-A3 genetic locus and lung cancer risk. Cancer (2010) 1.55
Palliative care inpatient service in a comprehensive cancer center: clinical and financial outcomes. J Clin Oncol (2004) 1.55
Inpatient rehabilitation improved functional status in asthenic patients with solid and hematologic malignancies. Am J Phys Med Rehabil (2011) 1.54
Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis (2002) 1.52
Myozenin 2 is a novel gene for human hypertrophic cardiomyopathy. Circ Res (2007) 1.51
Haplotypes of two variants in p16 (CDKN2/MTS-1/INK4a) exon 3 and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Epidemiol Biomarkers Prev (2002) 1.51
Psychosocial effects of cancer cachexia: a systematic literature search and qualitative analysis. J Pain Symptom Manage (2012) 1.50
Non-steroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review. Acta Oncol (2012) 1.49
Impact of timing and setting of palliative care referral on quality of end-of-life care in cancer patients. Cancer (2014) 1.49
Discharge outcomes and survival of patients with advanced cancer admitted to an acute palliative care unit at a comprehensive cancer center. J Palliat Med (2010) 1.48
The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer (2003) 1.47
Update on cancer pain guidelines. J Pain Symptom Manage (2009) 1.46
Cancer patients' perceptions regarding the value of the physical examination: a survey study. Cancer (2014) 1.44
GLIOGENE an International Consortium to Understand Familial Glioma. Cancer Epidemiol Biomarkers Prev (2007) 1.42
Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol Pain (2008) 1.41